. .
Bruker Daltonics
Bruker

Analysis of Alzheimer’s Disease Markers in Complex Biological Samples using Derivatized Arrays

Type: Application

Poster

Expression Proteomics

Number: Technology

ASMS 2010

MALDI-TOF

Year Products

2010

  Author
 

Mariana Rusa(1), Steve Roth(1), Amanda Bulman(1), Enrique Dalmasso(1), Matt Hammond(1), Fiona Plows(1) and Martin Schuerenberg(2); 1Bio-Rad Laboratories, Inc, Hercules, CA, USA; 2Bruker Daltonics, Bremen, Germany

  Reference
 

ASMS 2010

 

Abstract

 

IntroductionThe use of derizatived arrays and time-of-flight mass spectrometry for the top-down profiling of intact proteins has previously yielded a large number of candidate biomarkers, biological indicators of a phenotypically altered state, from complex biological samples. We show here that this combination is also of value for the targeted assay of established biomarkers such as amyloid beta peptides. Amyloid beta peptides can be difficult to study using standard methods due to their multiplicity and small size. Numerous fragments potentially contained in samples creates issues of cross-reactivity and incomplete results with traditional methods such as ELISA. Detection by mass spectrometry has the advantage of enabling the clear distinction between fragments that may share the same antibody recognition sequence. Multiple amyloid beta peptides can be captured simultaneously from biological samples using a targeted proteomics approach combining immunological sample enrichment and MALDI: Mass Spectrometry In-Situ ImmunoAssay (MaS-ISIA).

 

Related Products

 

 

Download

 

Register with us
In order to get access to all our multimedia specials, additional content and to subscribe to our informative Daltonics E-Dispatch newsletter, please register to our website.